Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 19

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 19
---
 as of such date. No fractional shares were issued in connection with the reverse stock
split.

Concurrently
with the reverse split, and in an effort to bring the Depositary Shares price into compliance with NASDAQ’s minimum requirement
for 500,000 listed Depositary Shares, on March 27, 2023, we effected a ratio change in the number of our ordinary shares represented by
the Depositary Shares from 25 ordinary shares per Depositary Share to five ordinary shares per Depositary Share. No fractional Depositary
Shares were issued.

Between
March 27, 2023 and December 31, 2024, we have issued 95,137,075 Ordinary Shares upon the exercise of pre-funded warrants, Series A Warrants
and Series B Warrants issued in the February Private Placement.

On
May 26, 2023, we completed the closing of a registered direct offering with institutional investors of (1) 166,017,700 Ordinary Shares
represented by 16,601 Depositary Shares, issuable upon the exercise of the Series C warrants, or Series C Warrants, at an exercise price
of $400.00 per warrant, (2) 110,675,600 Ordinary Shares represented by 11,059 Depositary Shares issuable upon the exercise of the Series
D warrants, or Series D Warrants at an exercise price of $400.00 per warrant and, (3) 4,426,800 Ordinary Shares represented by 442 Depositary
Shares issuable upon the exercise of warrants issued to the placement agent in the offering at an exercise price of $375.00 per warrant,
or May 2023 Placement Agent Warrants.

On June 14, 2023, we held our June AGM, and our
shareholders passed resolutions, among other procedural items, to approve the allotment of, and disapplication of pre-emption rights in
respect of, up to 7.0 billion Ordinary Shares. On June 14, 2023, we also held a June GM, and our shareholders passed resolutions to, among
other things, (i) re-designate our deferred shares into A Deferred Shares, and (ii) subdivide our Ordinary Shares of £0.02 nominal
value each into one Ordinary Share of £0.001 nominal value and 19 B Deferred Shares of £0.001 nominal value each.

On
June 20, 2023, we issued the Series C Warrants, Series D